Copyright
©The Author(s) 2019.
World J Gastroenterol. Mar 14, 2019; 25(10): 1224-1237
Published online Mar 14, 2019. doi: 10.3748/wjg.v25.i10.1224
Published online Mar 14, 2019. doi: 10.3748/wjg.v25.i10.1224
Figure 2 Peroxiredoxin 1 as a putative target of microRNA-596 in gastric cancer cells.
A: The predicted binding sites for microRNA-596 (miR-596) in the 3'-UTR of peroxiredoxin 1 (PRDX1). B: Expression of PRDX1 protein in human gastric cancer (GC) cells. C: Quantitative real-time PCR (qRT-PCR) for determining miR-596 expression in MKN-45 and MGC-803 cells transfected with miR-NC or miR-596 mimics. D: PRDX1 mRNA and protein expression in MKN-45 and MGC-803 cells transfected with miR-NC or miR-596 mimics. β-actin was used as an internal control. E: Relative luciferase activity of PRDX1 in wild-type (WT-UTR) or mutant (MUT-UTR). aP < 0.05, bP < 0.01, cP < 0.001 vs miR-NC. PRDX1: Peroxiredoxin 1; MiR-596: MicroRNA-596.
- Citation: Zhang Z, Dai DQ. MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation. World J Gastroenterol 2019; 25(10): 1224-1237
- URL: https://www.wjgnet.com/1007-9327/full/v25/i10/1224.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i10.1224